We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 29,501

Remicade Biosimilar Closer To Approval, But Patent Dance Goes On
  • Foley & Lardner LLP
  • USA
  • February 11 2016

Celltrion’s biosimilar version of Janssen’s Remicade (infliximab) product cleared a significant regulatory hurdle on February 9, 2016, when the Food


Proposal to align New Zealand and Australian patent law
  • AJ Park
  • Australia, New Zealand
  • February 11 2016

The Patents Act 2013 was intended to significantly overhaul New Zealand's patent laws which, until recently, were operating under the Patents Act 1953


12 signposts to stop your computer implemented inventions from going down the bad road of Non-Patentable Subject Matter in Australia
  • Phillips Ormonde Fitzpatrick
  • Australia
  • February 10 2016

The Australian Patent Office has updated their Patent Manual of Practice and Procedure on 1 February 2016 to include the following signposts to


IP Australia trialing pre-examination notifications
  • AJ Park
  • Australia
  • February 10 2016

IP Australia is currently trialing issuing pre-examination notifications to patent applicants two months before their patent application is due to be


Patenting the Avocado: A California Story with a Classic Recipe
  • Lane Powell PC
  • USA
  • February 10 2016

Guacamole and chips are the ultimate in Super Bowl Sunday comfort food nowadays. During the PanthersBroncos game, the California Avocado Commission


First Reading of the Patents (Trans-Tasman Patent Attorneys and Other Matters) Amendment Bill
  • Baldwins
  • Australia, New Zealand
  • February 10 2016

The Patents (Trans-Tasman Patent Attorneys and Other Matters) Amendment Bill ("Bill") was read for the first time in Parliament on 9 February 2016


Dealing with a cease and desist letter: part 1
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 10 2016

When a company receives a cease and desist letter, the first questions that typically come to mind are as follows: Do you have to respond to the


Right to fair reward for employee inventor
  • Jacobacci & Partners
  • Italy
  • February 10 2016

A recent decision of the Court of Milan addressed the right to a fair reward which is available, in certain circumstances specified by patent law, to


Chestnut v. Apple: District Court Puts Plaintiff to the Test--Proceed on Limited Number of Claims or Continue Stay pending Inter Partes Review
  • Jeffer Mangels Butler & Mitchell LLP
  • USA
  • February 10 2016

In this patent infringement action, the plaintiff asserted claims from two different patents against Apple. Apple filed an Inter Partes Review


First Monoclonal Antibody Biosimilar in U.S. Gets One Step Closer to FDA Approval
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 10 2016

Yesterday, the FDA's Arthritis Advisory Committee voted 21-3 to recommend that CT-P13, Celltrion's proposed biosimilar of Janssen Biotech, Inc.'s